Key players in the global human vaccine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global human vaccine market. A few expansion strategies adopted by players operating in the global human vaccine market are:
The report on the global human vaccine market discussed individual strategies, followed by company profiles of manufacturers of human vaccine. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global human vaccine market.
Human vaccine market to reach the valuation of US$ 81,346.4 Mn by 2027
Human vaccine market is anticipated to expand at a CAGR of 8.7% from 2019 to 2027
Human vaccine market is driven by extremely low risk of serious and fatal side effects associated with vaccines
Key players operating in the human vaccines market include Sanofi S. A., Pfizer, Inc., Novartis AG, Mymetics, Merck & Co, Inc., Johnson & Johnson, GlaxoSmithKline Plc., Bharat Biotech, and Bavarian Nordic.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary : Global Human Vaccine Market
4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Human Vaccine Market Analysis and Forecasts, 2018–2030
5. Key Insights
5.1. Product Overview
5.2. Key Industry Developments
5.3. Emerging Trends in Human Vaccines Market
6. Global Human Vaccine Market Analysis and Forecasts, By Vaccine
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Vaccine, 2018–2030
6.3.1. Conjugate
6.3.2. Recombinant
6.3.3. Inactivated
6.3.4. Combination
6.3.5. Attenuated
6.3.6. Others
6.4. Market Attractiveness By Vaccine
7. Global Human Vaccine Market Analysis and Forecasts, By Product
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Product, 2018–2030
7.3.1. Pneumococcal
7.3.2. Influenza
7.3.3. Hepatitis
7.3.4. HPV
7.3.5. Meningococcal
7.3.6. Rotavirus
7.3.7. Measles and Rubella
7.3.8. Typhoid
7.3.9. Combination
7.3.10. Others
7.4. Market Attractiveness By Product
8. Global Human Vaccine Market Analysis and Forecasts, By Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By Distribution Channel, 2018–2030
8.3.1. Hospital Pharmacies
8.3.2. Drugstores
8.3.3. Others
8.4. Market Attractiveness By Distribution Channel
9. Global Human Vaccine Market Analysis and Forecasts, By Age Group
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast By Age Group, 2018–2030
9.3.1. Pediatrics
9.3.2. Adolescents
9.3.3. Adults
9.3.4. Geriatrics
9.4. Market Attractiveness By Age Group
10. Global Human Vaccine Market Analysis and Forecasts, By Region
10.1. Key Findings
10.2. Market Value Forecast By Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness By Region
11. North America Human Vaccine Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast By Vaccine, 2018–2030
11.2.1. Conjugate
11.2.2. Recombinant
11.2.3. Inactivated
11.2.4. Combination
11.2.5. Attenuated
11.2.6. Others
11.3. Market Value Forecast By Product, 2018–2030
11.3.1. Pneumococcal
11.3.2. Influenza
11.3.3. Hepatitis
11.3.4. HPV
11.3.5. Meningococcal
11.3.6. Rotavirus
11.3.7. Measles and Rubella
11.3.8. Typhoid
11.3.9. Combination
11.3.10. Others
11.4. Market Value Forecast By Distribution Channel, 2018–2030
11.4.1. Hospital Pharmacies
11.4.2. Drugstores
11.4.3. Others
11.5. Market Value Forecast By Age Group, 2018–2030
11.5.1. Pediatrics
11.5.2. Adolescents
11.5.3. Adults
11.5.4. Geriatrics
11.6. Market Value Forecast By Country, 2018–2030
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Vaccine
11.7.2. By Product
11.7.3. By Distribution Channel
11.7.4. By Age Group
11.7.5. By Country
12. Europe Human Vaccine Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast By Vaccine, 2018–2030
12.2.1. Conjugate
12.2.2. Recombinant
12.2.3. Inactivated
12.2.4. Combination
12.2.5. Attenuated
12.2.6. Others
12.3. Market Value Forecast By Product, 2018–2030
12.3.1. Pneumococcal
12.3.2. Influenza
12.3.3. Hepatitis
12.3.4. HPV
12.3.5. Meningococcal
12.3.6. Rotavirus
12.3.7. Measles and Rubella
12.3.8. Typhoid
12.3.9. Combination
12.3.10. Others
12.4. Market Value Forecast By Distribution Channel, 2018–2030
12.4.1. Hospital Pharmacies
12.4.2. Drugstores
12.4.3. Others
12.5. Market Value Forecast By Age Group, 2018–2030
12.5.1. Pediatrics
12.5.2. Adolescents
12.5.3. Adults
12.5.4. Geriatrics
12.6. Market Value Forecast By Country, 2018–2030
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Spain
12.6.5. Italy
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Vaccine
12.7.2. By Product
12.7.3. By Distribution Channel
12.7.4. By Age Group
12.7.5. By Country
13. Asia Pacific Human Vaccine Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast By Vaccine, 2018–2030
13.2.1. Conjugate
13.2.2. Recombinant
13.2.3. Inactivated
13.2.4. Combination
13.2.5. Attenuated
13.2.6. Others
13.3. Market Value Forecast By Product, 2018–2030
13.3.1. Pneumococcal
13.3.2. Influenza
13.3.3. Hepatitis
13.3.4. HPV
13.3.5. Meningococcal
13.3.6. Rotavirus
13.3.7. Measles and Rubella
13.3.8. Typhoid
13.3.9. Combination
13.3.10. Others
13.4. Market Value Forecast By Distribution Channel, 2018–2030
13.4.1. Hospital Pharmacies
13.4.2. Drugstores
13.4.3. Others
13.5. Market Value Forecast By Age Group, 2018–2030
13.5.1. Pediatrics
13.5.2. Adolescents
13.5.3. Adults
13.5.4. Geriatrics
13.6. Market Value Forecast By Country, 2018–2030
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Vaccine
13.7.2. By Product
13.7.3. By Distribution Channel
13.7.4. By Age Group
13.7.5. By Country
14. Latin America Human Vaccine Market Analysis and Forecast
14.1. Introduction
14.2. Market Value Forecast By Vaccine, 2018–2030
14.2.1. Conjugate
14.2.2. Recombinant
14.2.3. Inactivated
14.2.4. Combination
14.2.5. Attenuated
14.2.6. Others
14.3. Market Value Forecast By Product, 2018–2030
14.3.1. Pneumococcal
14.3.2. Influenza
14.3.3. Hepatitis
14.3.4. HPV
14.3.5. Meningococcal
14.3.6. Rotavirus
14.3.7. Measles and Rubella
14.3.8. Typhoid
14.3.9. Combination
14.3.10. Others
14.4. Market Value Forecast By Distribution Channel, 2018–2030
14.4.1. Hospital Pharmacies
14.4.2. Drugstores
14.4.3. Others
14.5. Market Value Forecast By Age Group, 2018–2030
14.5.1. Pediatrics
14.5.2. Adolescents
14.5.3. Adults
14.5.4. Geriatrics
14.6. Market Value Forecast By Country, 2018–2030
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Vaccine
14.7.2. By Product
14.7.3. By Distribution Channel
14.7.4. By Age Group
14.7.5. By Country
15. Middle East & Africa Human Vaccine Market Analysis and Forecast
15.1. Introduction
15.2. Market Value Forecast By Vaccine, 2018–2030
15.2.1. Conjugate
15.2.2. Recombinant
15.2.3. Inactivated
15.2.4. Combination
15.2.5. Attenuated
15.2.6. Others
15.3. Market Value Forecast By Product, 2018–2030
15.3.1. Pneumococcal
15.3.2. Influenza
15.3.3. Hepatitis
15.3.4. HPV
15.3.5. Meningococcal
15.3.6. Rotavirus
15.3.7. Measles and Rubella
15.3.8. Typhoid
15.3.9. Combination
15.3.10. Others
15.4. Market Value Forecast By Distribution Channel, 2018–2030
15.4.1. Hospital Pharmacies
15.4.2. Drugstores
15.4.3. Others
15.5. Market Value Forecast By Age Group, 2018–2030
15.5.1. Pediatrics
15.5.2. Adolescents
15.5.3. Adults
15.5.4. Geriatrics
15.6. Market Value Forecast By Country, 2018–2030
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Vaccine
15.7.2. By Product
15.7.3. By Distribution Channel
15.7.4. By Age Group
15.7.5. By Country
16. Competition Landscape
16.1. Market Share Analysis By Company (2019)
16.2. Company Profiles
16.2.1. AstraZeneca plc
16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.1.2. Growth Strategies
16.2.1.3. SWOT Analysis
16.2.2. Bavarian Nordic
16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2.2. Growth Strategies
16.2.2.3. SWOT Analysis
16.2.3. Bharat Biotech
16.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.3.2. Growth Strategies
16.2.3.3. SWOT Analysis
16.2.4. CSL Limited
16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.4.2. Growth Strategies
16.2.4.3. SWOT Analysis
16.2.5. Emergent BioSolutions, Inc.
16.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.5.2. Growth Strategies
16.2.5.3. SWOT Analysis
16.2.6. GlaxoSmithKline plc.
16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.6.2. Growth Strategies
16.2.6.3. SWOT Analysis
16.2.7. Johnson & Johnson
16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.7.2. Growth Strategies
16.2.7.3. SWOT Analysis
16.2.8. Merck & Co, Inc.
16.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.8.2. Growth Strategies
16.2.8.3. SWOT Analysis
16.2.9. Mymetics
16.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.9.2. Growth Strategies
16.2.9.3. SWOT Analysis
16.2.10. Novartis AG
16.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.10.2. Growth Strategies
16.2.10.3. SWOT Analysis
16.2.11. Pfizer, Inc.
16.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.11.2. Growth Strategies
16.2.11.3. SWOT Analysis
16.2.12. Sanofi S.A.
16.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.12.2. Growth Strategies
16.2.12.3. SWOT Analysis
16.2.13. Shenzhen Kangtai Biological Products Co., Ltd.
16.2.13.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.13.2. Growth Strategies
16.2.13.3. SWOT Analysis
16.2.14. Takeda Pharmaceutical Company Limited
16.2.14.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.14.2. Growth Strategies
16.2.14.3. SWOT Analysis
List of Tables
Table 01 Global Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 02 Global Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 03 Global Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 04 Global Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 05 Global Human Vaccines Market Size (US$ Mn) Forecast, by Region, 2019–2027
Table 06 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 07 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 08 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 09 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 10 Asia Pacific Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 11 North America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 12 North America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 13 North America Human Vaccines Market Size (US$) Forecast, by Vaccine Type, 2019–2027
Table 14 North America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 15 North America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 16 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 17 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 18 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 19 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 20 Europe Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 21 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 22 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 23 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 24 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 25 Latin America Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
Table 26 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Country, 2019–2027
Table 27 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Product, 2019–2027
Table 28 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Vaccine Type, 2019–2027
Table 29 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Age Group, 2019–2027
Table 30 MEA Human Vaccines Market Size (US$ Mn) Forecast, by Distribution Channel, 2019–2027
List of Figure
Figure 01 Global Human Vaccines Market Value Share Analysis, by Vaccine Type, 2018 and 2027
Figure 02 Global Conjugate Market Revenue (US$ Mn), 2017–2027
Figure 03 Global Recombinant Market Revenue (US$ Mn), 2017–2027
Figure 04 Global Inactivated Market Revenue (US$ Mn), 2017–2027
Figure 05 Global Combination Market Revenue (US$ Mn), 2017–2027
Figure 06 Global Attenuated Market Revenue (US$ Mn), 2017–2027
Figure 07 Global Others Market Revenue (US$ Mn), 2017–2027
Figure 08 Human Vaccines Market Attractiveness Analysis, by Vaccine Type, 2018
Figure 09 Global Human Vaccines Market Value Share Analysis, by Product, 2018 and 2027
Figure 10 Global Pneumococcal Market Revenue (US$ Mn), 2017–2027
Figure 11 Global Influenza Market Revenue (US$ Mn), 2017–2027
Figure 12 Global Hepatitis Market Revenue (US$ Mn), 2017–2027
Figure 13 Global HPV Market Revenue (US$ Mn), 2017–2027
Figure 14 Global Meningococcal Market Revenue (US$ Mn), 2017–2027
Figure 15 Global Rotavirus Market Revenue (US$ Mn), 2017–2027
Figure 16 Global Measles and Rubella Market Revenue (US$ Mn), 2017–2027
Figure 17 Global Typhoid Market Revenue (US$ Mn), 2017–2027
Figure 18 Global Combination Market Revenue (US$ Mn), 2017–2027
Figure 19 Global Others Market Revenue (US$ Mn), 2017–2027
Figure 20 Human Vaccines Market Attractiveness Analysis, by Product, 2018
Figure 21 Global Human Vaccines Market Value Share Analysis, by Distribution Channel, 2018 and 2027
Figure 22 Global Hospital Pharmacies Market Revenue (US$ Mn), 2017–2027
Figure 23 Global Drugstores Market Revenue (US$ Mn), 2017–2027
Figure 24 Global others Market Revenue (US$ Mn), 2017–2027
Figure 25 Human Vaccines Market Attractiveness Analysis, by Distribution Channel, 2018
Figure 26 Global Human Vaccines Market Value Share Analysis, by Age Group, 2018 and 2027
Figure 27 Global Pediatrics Market Revenue (US$ Mn), 2017–2027
Figure 28 Global Adolescents Market Revenue (US$ Mn), 2017–2027
Figure 29 Global Adults Market Revenue (US$ Mn), 2017–2027
Figure 30 Global Geriatrics Market Revenue (US$ Mn), 2017–2027
Figure 31 Human Vaccines Market Attractiveness Analysis, by Age Group, 2018
Figure 32 North America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 33 Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 34 APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 35 Latin America Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 36 MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 37 Global Human Vaccines Market Attractiveness Analysis, by Region
Figure 38 China Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 39 Japan Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 40 ASEAN Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 41 Rest of APAC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 42 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Country
Figure 43 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Product
Figure 44 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Vaccine Type
Figure 45 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Age Group
Figure 46 Asia Pacific Human Vaccines Market Attractiveness Analysis, by Distribution Channel
Figure 47 U.S. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 48 Canada Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 49 North America Human Vaccines Market Attractiveness Analysis, by Country
Figure 50 North America Human Vaccines Market Attractiveness Analysis, by Product
Figure 51 North America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
Figure 52 North America Human Vaccines Market Attractiveness Analysis, by Age Group
Figure 53 North America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
Figure 54 Germany Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 55 France Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 56 U.K. Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 57 Italy Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 58 Spain Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 59 Rest of Europe Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 60 Europe Human Vaccines Market Attractiveness Analysis, by Country
Figure 61 Europe Human Vaccines Market Attractiveness Analysis, by Product
Figure 62 Europe Human Vaccines Market Attractiveness Analysis, by Vaccine Type
Figure 63 Europe Human Vaccines Market Attractiveness Analysis, by Age Group
Figure 64 Europe Human Vaccines Market Attractiveness Analysis, by Distribution Channel
Figure 65 Brazil Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 66 Mexico Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 67 Rest of LATAM Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 68 Latin America Human Vaccines Market Attractiveness Analysis, by Country
Figure 69 Latin America Human Vaccines Market Attractiveness Analysis, by Product
Figure 70 Latin America Human Vaccines Market Attractiveness Analysis, by Vaccine Type
Figure 71 Latin America Human Vaccines Market Attractiveness Analysis, by Age Group
Figure 72 Latin America Human Vaccines Market Attractiveness Analysis, by Distribution Channel
Figure 73 GCC Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 74 South Africa Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 75 Rest of MEA Human Vaccines Market Size (US$ Mn) Forecast, 2019–2027
Figure 76 MEA Human Vaccines Market Attractiveness Analysis, by Country
Figure 77 MEA Human Vaccines Market Attractiveness Analysis, by Product
Figure 78 MEA Human Vaccines Market Attractiveness Analysis, by Vaccine Type
Figure 79 MEA Human Vaccines Market Attractiveness Analysis, by Age Group
Figure 80 MEA Human Vaccines Market Attractiveness Analysis, by Distribution Channel
Figure 81 Human Vaccine Market Share Analysis, by Company (2018)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Human Vaccines Market
